Weekly Investment Analysts’ Ratings Updates for Insulet (PODD)

Several brokerages have updated their recommendations and price targets on shares of Insulet (NASDAQ: PODD) in the last few weeks:

• 2/24/2025 – Insulet was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 2/21/2025 – Insulet had its price target raised by analysts at Wells Fargo & Company from $305.00 to $322.00. They now have an “overweight” rating on the stock.
• 2/21/2025 – Insulet had its price target raised by analysts at Piper Sandler from $285.00 to $310.00. They now have an “overweight” rating on the stock.
• 2/21/2025 – Insulet had its “outperform” rating reaffirmed by analysts at Raymond James. They now have a $328.00 price target on the stock, up previously from $294.00.
• 2/21/2025 – Insulet had its price target raised by analysts at Stifel Nicolaus from $245.00 to $293.00. They now have a “hold” rating on the stock.
• 2/21/2025 – Insulet had its price target raised by analysts at Citigroup Inc. from $310.00 to $355.00. They now have a “buy” rating on the stock.
• 2/21/2025 – Insulet had its price target raised by analysts at Canaccord Genuity Group Inc. from $304.00 to $324.00. They now have a “buy” rating on the stock.
• 1/3/2025 – Insulet had its price target raised by analysts at TD Cowen from $264.00 to $324.00. They now have a “buy” rating on the stock.

Insulet Trading Up 0.2 %

NASDAQ PODD opened at $283.48 on Tuesday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market capitalization of $19.88 billion, a P/E ratio of 48.96, a PEG ratio of 3.62 and a beta of 1.23. The firm’s 50-day moving average is $273.33 and its two-hundred day moving average is $248.46. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The firm had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. On average, sell-side analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by insiders.

Institutional Trading of Insulet

Several hedge funds have recently modified their holdings of the stock. QRG Capital Management Inc. purchased a new stake in Insulet during the 3rd quarter worth about $297,000. Sumitomo Mitsui DS Asset Management Company Ltd grew its position in shares of Insulet by 30.1% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier’s stock worth $2,192,000 after buying an additional 1,942 shares in the last quarter. Fisher Asset Management LLC increased its stake in shares of Insulet by 0.9% during the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock worth $81,719,000 after buying an additional 3,113 shares during the period. Orion Portfolio Solutions LLC increased its stake in shares of Insulet by 86.2% during the third quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock worth $1,822,000 after buying an additional 3,623 shares during the period. Finally, Nomura Asset Management Co. Ltd. raised its holdings in Insulet by 5.7% in the third quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier’s stock valued at $35,708,000 after acquiring an additional 8,301 shares in the last quarter.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.